Martins-Filho, Paulo Ricardo published the artcileEfficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials, Synthetic Route of 55981-09-4, the main research area is COVID-19; Meta-analysis; Nitazoxanide; SARS-CoV-2 infection.
Abstract: Purpose: Nitazoxanide is a broad-spectrum antiparasitic that has been tested for COVID-19 due to its anti-inflammatory effects and in vitro antiviral activity. This study synthesized the best evidence on the efficacy and safety of nitazoxanide in COVID-19. Methods: Searches for studies were performed in peer-reviewed and gray-literature from Jan. 1, 2020 to May 23, 2022. The following elements were used to define eligibility criteria: (1) Population: individuals with COVID-19; (2) Intervention: nitazoxanide; (3) Comparison: placebo; (4) Outcomes: primary outcome was death, and secondary outcomes were viral load, pos. RT-PCR status, serum biomarkers of inflammation, composite measure of disease progression (ICU admission or invasive mech. ventilation), and any adverse events; (5) Study type: blinded, placebo-controlled, randomized clin. trials (RCTs). Treatment effects were reported as relative risk (RR) for dichotomous variables and standardized mean difference (SMD) for continuous variables with 95% confidence intervals (CI). Results: Five blinded, placebo-controlled RCTs were included and enrolled individuals with mild or moderate SARS-CoV-2 infection. We found no difference between nitazoxanide and placebo in reducing viral load (SMD = – 0.16; 95% CI – 0.38 to 0.05) and the frequency of pos. RTP-PCR results (RR = 0.92; 95% CI 0.81 to 1.06). In addition, there was no decreased risk for disease progression (RR = 0.63; 95% CI 0.38 to 1.04) and death (RR = 0.81; 95% CI 0.36 to 1.78) among patients receiving nitazoxanide. Patients with COVID-19 treated with nitazoxanide had decreased levels of white blood cells (SMD = – 0.15; 95% – 0.29 to – 0.02), lactate dehydrogenase (LDH) (SMD – 0.32; 95% – 0.52 to – 0.13), and D-dimer (SMD – 0.49; 95% CI – 0.68 to – 0.31) compared to placebo, but the magnitude of effect was considered small to moderate. Conclusion: This systematic review showed no evidence of clin. benefits of the use of nitazoxanide to treat patients with mild or moderate COVID-19. In addition, we found a reduction in WBC, LDH, and D-dimer levels among nitazoxanide-treated patients, but the effect size was considered small to moderate.
European Journal of Clinical Pharmacology published new progress about COVID-19; Meta-analysis; Nitazoxanide; SARS-CoV-2 infection. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Synthetic Route of 55981-09-4.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics